当前蛋白身份:P14735 重新检索
本组结构的主要差异维度
构建体不同 突变/修饰不同 组装状态不同 配体/离子不同 实验方法不同 实验环境不同 结构质量指标不同

差异标签只比较当前检索结果;所有PDB和assembly原始记录仍分别保留。

相关结构差异明细

一行代表一个 PDB 条目中的一个 biological assembly;同一蛋白的多个单体会分别列出。

PDB 条目 Assembly / 聚集状态 构建体 突变与修饰 配体、离子与非聚合物 实验方法 实验环境 结构质量
2G47 Crystal structure of human insulin-degrading enzyme in complex with amyloid-beta (1-40) 提交 2006-02-21 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 41–1018(978 aa)
突变:E111Q DIO 1,4-DIETHYLENE DIOXIDE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;298 K;10% PEGMME 5000, 0.1M HEPES, 10% diaoxane, 5% tacsimate, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
分辨率 2.10 Å R-free 0.223
2G47 Crystal structure of human insulin-degrading enzyme in complex with amyloid-beta (1-40) 提交 2006-02-21 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 41–1018(978 aa)
突变:E111Q DIO 1,4-DIETHYLENE DIOXIDE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;298 K;10% PEGMME 5000, 0.1M HEPES, 10% diaoxane, 5% tacsimate, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
分辨率 2.10 Å R-free 0.223
2JG4 Substrate-free IDE structure in its closed conformation 提交 2007-02-07 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 42–1018(977 aa) 片段:RESIDUES 42-1018
突变:YES ZN ZINC ION × 1 DIO 1,4-DIETHYLENE DIOXIDE × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;298 K;10% PEGMME 5000, 0.1M HEPES, 10%, DIAOXANE, 5% TACSIMATE, PH 7.0, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
分辨率 2.80 Å R-free 0.227
2JG4 Substrate-free IDE structure in its closed conformation 提交 2007-02-07 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 42–1018(977 aa) 片段:RESIDUES 42-1018
突变:YES ZN ZINC ION × 1 DIO 1,4-DIETHYLENE DIOXIDE × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;298 K;10% PEGMME 5000, 0.1M HEPES, 10%, DIAOXANE, 5% TACSIMATE, PH 7.0, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
分辨率 2.80 Å R-free 0.227
2WBY Crystal structure of human insulin-degrading enzyme in complex with insulin 提交 2009-03-06 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 A 42–1019(978 aa) 片段:RESIDUES 42-1019
突变:YES ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 7;10-13% PEG MME 5000, 100 MM HEPES PH 7.0, 4-14% TACSIMATE, 10% DIOXANE
分辨率 2.60 Å R-free 0.218
2WBY Crystal structure of human insulin-degrading enzyme in complex with insulin 提交 2009-03-06 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 B 42–1019(978 aa) 片段:RESIDUES 42-1019
突变:YES ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 7;10-13% PEG MME 5000, 100 MM HEPES PH 7.0, 4-14% TACSIMATE, 10% DIOXANE
分辨率 2.60 Å R-free 0.218
2WC0 crystal structure of human insulin degrading enzyme in complex with iodinated insulin 提交 2009-03-06 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 A 42–1019(978 aa) 片段:RESIDUES 42-1019
突变:YES ZN ZINC ION × 1 DIO 1,4-DIETHYLENE DIOXIDE × 4 X-RAY DIFFRACTION
X-ray结晶条件 pH 7;pH 7
分辨率 2.80 Å R-free 0.220
2WC0 crystal structure of human insulin degrading enzyme in complex with iodinated insulin 提交 2009-03-06 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 B 42–1019(978 aa) 片段:RESIDUES 42-1019
突变:YES ZN ZINC ION × 1 DIO 1,4-DIETHYLENE DIOXIDE × 4 X-RAY DIFFRACTION
X-ray结晶条件 pH 7;pH 7
分辨率 2.80 Å R-free 0.220
2WK3 Crystal structure of human insulin-degrading enzyme in complex with amyloid-beta (1-42) 提交 2009-06-05 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 1–1019(1019 aa)
突变:YES ZN ZINC ION × 1 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 2.59 Å R-free 0.232
2WK3 Crystal structure of human insulin-degrading enzyme in complex with amyloid-beta (1-42) 提交 2009-06-05 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 1–1019(1019 aa)
突变:YES ZN ZINC ION × 1 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 2.59 Å R-free 0.232
2YPU human insulin degrading enzyme E111Q in complex with inhibitor compound 41367 提交 2012-11-01 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 42–1019(978 aa) 片段:RESIDUES 42-1019
突变:YES ZN ZINC ION × 1 I41 2-[[2-[[(2S)-3-(3H-IMIDAZOL-4-YL)-1-METHOXY-1-OXO-PROPAN-2-YL]AMINO]-2-OXO-ETHYL]-(PHENYLMETHYL)AMINO]ETHANOIC ACID × 1 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 2.80 Å R-free 0.225
2YPU human insulin degrading enzyme E111Q in complex with inhibitor compound 41367 提交 2012-11-01 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 42–1019(978 aa) 片段:RESIDUES 42-1019
突变:YES ZN ZINC ION × 1 I41 2-[[2-[[(2S)-3-(3H-IMIDAZOL-4-YL)-1-METHOXY-1-OXO-PROPAN-2-YL]AMINO]-2-OXO-ETHYL]-(PHENYLMETHYL)AMINO]ETHANOIC ACID × 1 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 2.80 Å R-free 0.225
3CWW Crystal Structure of IDE-bradykinin complex 提交 2008-04-23 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 42–1019(978 aa)
链 B 42–1019(978 aa)
突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A 突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A ZN ZINC ION × 2 ACT ACETATE ION × 4 DIO 1,4-DIETHYLENE DIOXIDE × 5 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION;pH 7;291 K;13% PEGMME 5000, 100mM HEPES, pH 7.0, 10%, Tacsimate, 10% dioxane, vapor diffusion, temperature 291K
分辨率 1.96 Å R-free 0.208
3E4A Human IDE-inhibitor complex at 2.6 angstrom resolution 提交 2008-08-11 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 1–1019(1019 aa)
突变:C110L, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A ZN ZINC ION × 1 QIX N~2~-[(2R)-4-(HYDROXYAMINO)-2-(2-NAPHTHYLMETHYL)-4-OXOBUTANOYL]-L-ARGINYLGLYCYLGLYCINAMIDE × 1 DIO 1,4-DIETHYLENE DIOXIDE × 2 ACY ACETIC ACID × 8 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291.5 K;PEG MME 5000, HEPES PH 7.0, TACSIMATE, DIOXANE, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 291K, pH 7.00, temperature 291.5K
分辨率 2.60 Å R-free 0.225
3E4A Human IDE-inhibitor complex at 2.6 angstrom resolution 提交 2008-08-11 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 1–1019(1019 aa)
突变:C110L, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A ZN ZINC ION × 1 QIX N~2~-[(2R)-4-(HYDROXYAMINO)-2-(2-NAPHTHYLMETHYL)-4-OXOBUTANOYL]-L-ARGINYLGLYCYLGLYCINAMIDE × 1 DIO 1,4-DIETHYLENE DIOXIDE × 5 ACY ACETIC ACID × 6 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291.5 K;PEG MME 5000, HEPES PH 7.0, TACSIMATE, DIOXANE, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 291K, pH 7.00, temperature 291.5K
分辨率 2.60 Å R-free 0.225
3E50 Crystal structure of human insulin degrading enzyme in complex with transforming growth factor-alpha 提交 2008-08-12 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 42–1019(978 aa) 片段:UNP residues 42-1019
突变:E111Q ZN ZINC ION × 1 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 2.30 Å R-free 0.231
3E50 Crystal structure of human insulin degrading enzyme in complex with transforming growth factor-alpha 提交 2008-08-12 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 42–1019(978 aa) 片段:UNP residues 42-1019
突变:E111Q ZN ZINC ION × 1 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 2.30 Å R-free 0.231
3H44 Crystal Structure of Insulin Degrading Enzyme in Complex with macrophage inflammatory protein 1 alpha 提交 2009-04-17 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 42–1019(978 aa) 片段:residues 42-1019
链 B 42–1019(978 aa) 片段:residues 42-1019
突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A 突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A DIO 1,4-DIETHYLENE DIOXIDE × 6 ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291 K;13% PEGMME 5000, 100mM HEPES, pH 7.0, 10%, Tacsimate, 10% dioxane, VAPOR DIFFUSION, HANGING DROP, temperature 291K
分辨率 3.00 Å R-free 0.237
3H44 Crystal Structure of Insulin Degrading Enzyme in Complex with macrophage inflammatory protein 1 alpha 提交 2009-04-17 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 42–1019(978 aa) 片段:residues 42-1019
链 B 42–1019(978 aa) 片段:residues 42-1019
突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A 突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A DIO 1,4-DIETHYLENE DIOXIDE × 6 ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291 K;13% PEGMME 5000, 100mM HEPES, pH 7.0, 10%, Tacsimate, 10% dioxane, VAPOR DIFFUSION, HANGING DROP, temperature 291K
分辨率 3.00 Å R-free 0.237
3H44 Crystal Structure of Insulin Degrading Enzyme in Complex with macrophage inflammatory protein 1 alpha 提交 2009-04-17 Assembly 3 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 42–1019(978 aa) 片段:residues 42-1019
突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A DIO 1,4-DIETHYLENE DIOXIDE × 3 ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291 K;13% PEGMME 5000, 100mM HEPES, pH 7.0, 10%, Tacsimate, 10% dioxane, VAPOR DIFFUSION, HANGING DROP, temperature 291K
分辨率 3.00 Å R-free 0.237
3H44 Crystal Structure of Insulin Degrading Enzyme in Complex with macrophage inflammatory protein 1 alpha 提交 2009-04-17 Assembly 4 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 42–1019(978 aa) 片段:residues 42-1019
突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A DIO 1,4-DIETHYLENE DIOXIDE × 3 ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291 K;13% PEGMME 5000, 100mM HEPES, pH 7.0, 10%, Tacsimate, 10% dioxane, VAPOR DIFFUSION, HANGING DROP, temperature 291K
分辨率 3.00 Å R-free 0.237
3HGZ Crystal structure of human insulin-degrading enzyme in complex with amylin 提交 2009-05-14 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 43–1011(969 aa)
突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291 K;pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
分辨率 2.91 Å R-free 0.224
3HGZ Crystal structure of human insulin-degrading enzyme in complex with amylin 提交 2009-05-14 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 43–1011(969 aa)
突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291 K;pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
分辨率 2.91 Å R-free 0.224
3N56 Crystal Structure of human Insulin-degrading enzyme (IDE) in complex with human B-type natriuretic peptide (BNP) 提交 2010-05-24 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 42–1019(978 aa) 片段:UNP residues 42-1019
突变:C110L, E111Q, C171S, C178S, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A ZN ZINC ION × 1 DIO 1,4-DIETHYLENE DIOXIDE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291 K;13% PEGMME-5000, 10% TACSIMATE, 10% DIOXANE, 100 mM Na-HEPES, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
分辨率 3.10 Å R-free 0.243
3N56 Crystal Structure of human Insulin-degrading enzyme (IDE) in complex with human B-type natriuretic peptide (BNP) 提交 2010-05-24 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 42–1019(978 aa) 片段:UNP residues 42-1019
突变:C110L, E111Q, C171S, C178S, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A ZN ZINC ION × 1 DIO 1,4-DIETHYLENE DIOXIDE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291 K;13% PEGMME-5000, 10% TACSIMATE, 10% DIOXANE, 100 mM Na-HEPES, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
分辨率 3.10 Å R-free 0.243
3N57 Crystal Structure of human Insulin-degrading enzyme (IDE) in complex with human atrial natriuretic peptide (ANP) 提交 2010-05-24 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 42–1019(978 aa) 片段:UNP residues 42-1019
链 B 42–1019(978 aa) 片段:UNP residues 42-1019
突变:C110L, E111Q, C171S, C178S, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A 突变:C110L, E111Q, C171S, C178S, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291 K;13% PEGMME-5000, 10% TACSIMATE, 10% DIOXANE, 100 mM Na-HEPES, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
分辨率 3.03 Å R-free 0.242
3OFI Crystal structure of human insulin-degrading enzyme in complex with ubiquitin 提交 2010-08-15 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 42–1019(978 aa)
未记录 ZN ZINC ION × 1 DIO 1,4-DIETHYLENE DIOXIDE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291 K;10-13% PEG MME 5000, 100 MM HEPES PH 7.0. 4-14% Tacsimate, 10% Dioxane, vapor diffusion, hanging drop, temperature 291K
分辨率 2.35 Å R-free 0.240
3OFI Crystal structure of human insulin-degrading enzyme in complex with ubiquitin 提交 2010-08-15 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 42–1019(978 aa)
未记录 ZN ZINC ION × 1 DIO 1,4-DIETHYLENE DIOXIDE × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291 K;10-13% PEG MME 5000, 100 MM HEPES PH 7.0. 4-14% Tacsimate, 10% Dioxane, vapor diffusion, hanging drop, temperature 291K
分辨率 2.35 Å R-free 0.240
3QZ2 The structure of cysteine-free human insulin degrading enzyme 提交 2011-03-04 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 42–1019(978 aa) 片段:UNP residues 42-1019
链 B 42–1019(978 aa) 片段:UNP residues 42-1019
未记录 ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;298 K;10-13% PEG MME 5000, 100 mM HEPES pH 7.0, 4-14% Tacsimate, 10% dioxane, VAPOR DIFFUSION, HANGING DROP, temperature 298K
分辨率 3.20 Å R-free 0.241
4DTT Crystal structure of human insulin degrading enzyme (ide) in complex with compund 41367 提交 2012-02-21 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 42–1019(978 aa) 片段:UNP RESIDUES 42-1019
突变:C110L,C171S,C178A,C257V,C414L,C573N,C590S,C789S,C812A,C819A,C904S,C966N,C974A ZN ZINC ION × 1 I41 2-[[2-[[(2S)-3-(3H-IMIDAZOL-4-YL)-1-METHOXY-1-OXO-PROPAN-2-YL]AMINO]-2-OXO-ETHYL]-(PHENYLMETHYL)AMINO]ETHANOIC ACID × 2 X-RAY DIFFRACTION
X-ray结晶条件 pH 7;298 K;10-13% PEG MME 5000, 100 MM HEPES PH 7.0, 4-14% TACSIMATE, 10% DIOXANE, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
分辨率 3.22 Å R-free 0.242
4DTT Crystal structure of human insulin degrading enzyme (ide) in complex with compund 41367 提交 2012-02-21 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 42–1019(978 aa) 片段:UNP RESIDUES 42-1019
突变:C110L,C171S,C178A,C257V,C414L,C573N,C590S,C789S,C812A,C819A,C904S,C966N,C974A ZN ZINC ION × 1 I41 2-[[2-[[(2S)-3-(3H-IMIDAZOL-4-YL)-1-METHOXY-1-OXO-PROPAN-2-YL]AMINO]-2-OXO-ETHYL]-(PHENYLMETHYL)AMINO]ETHANOIC ACID × 2 X-RAY DIFFRACTION
X-ray结晶条件 pH 7;298 K;10-13% PEG MME 5000, 100 MM HEPES PH 7.0, 4-14% TACSIMATE, 10% DIOXANE, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
分辨率 3.22 Å R-free 0.242
4DTT Crystal structure of human insulin degrading enzyme (ide) in complex with compund 41367 提交 2012-02-21 Assembly 3 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 42–1019(978 aa) 片段:UNP RESIDUES 42-1019
链 B 42–1019(978 aa) 片段:UNP RESIDUES 42-1019
突变:C110L,C171S,C178A,C257V,C414L,C573N,C590S,C789S,C812A,C819A,C904S,C966N,C974A 突变:C110L,C171S,C178A,C257V,C414L,C573N,C590S,C789S,C812A,C819A,C904S,C966N,C974A ZN ZINC ION × 2 I41 2-[[2-[[(2S)-3-(3H-IMIDAZOL-4-YL)-1-METHOXY-1-OXO-PROPAN-2-YL]AMINO]-2-OXO-ETHYL]-(PHENYLMETHYL)AMINO]ETHANOIC ACID × 4 X-RAY DIFFRACTION
X-ray结晶条件 pH 7;298 K;10-13% PEG MME 5000, 100 MM HEPES PH 7.0, 4-14% TACSIMATE, 10% DIOXANE, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
分辨率 3.22 Å R-free 0.242
4DWK Structure of cystein free insulin degrading enzyme with compound bdm41671 ((s)-2-{2-[carboxymethyl-(3-phenyl-propyl)-amino]-acetylamino}-3-(1h-imidazol-4-yl)-propionic acid methyl ester) 提交 2012-02-24 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 42–1019(978 aa) 片段:UNP RESIDUES 42-1019
突变:C110L,E111Q,C171S,C178A,C257V,C414L,C573N,C590S,C789S,C812A,C819A,C904S,C966N,C974A MGK methyl N-(carboxymethyl)-N-(3-phenylpropyl)glycyl-L-histidinate × 1 ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;287 K;10-13% PEG MME 5000, 100 MM HEPES PH 7.0, 4-14% TACSIMATE, 10% DIOXANE, VAPOR DIFFUSION, HANGING DROP, temperature 287K
分辨率 3.00 Å R-free 0.227
4DWK Structure of cystein free insulin degrading enzyme with compound bdm41671 ((s)-2-{2-[carboxymethyl-(3-phenyl-propyl)-amino]-acetylamino}-3-(1h-imidazol-4-yl)-propionic acid methyl ester) 提交 2012-02-24 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 42–1019(978 aa) 片段:UNP RESIDUES 42-1019
突变:C110L,E111Q,C171S,C178A,C257V,C414L,C573N,C590S,C789S,C812A,C819A,C904S,C966N,C974A MGK methyl N-(carboxymethyl)-N-(3-phenylpropyl)glycyl-L-histidinate × 1 ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;287 K;10-13% PEG MME 5000, 100 MM HEPES PH 7.0, 4-14% TACSIMATE, 10% DIOXANE, VAPOR DIFFUSION, HANGING DROP, temperature 287K
分辨率 3.00 Å R-free 0.227
4DWK Structure of cystein free insulin degrading enzyme with compound bdm41671 ((s)-2-{2-[carboxymethyl-(3-phenyl-propyl)-amino]-acetylamino}-3-(1h-imidazol-4-yl)-propionic acid methyl ester) 提交 2012-02-24 Assembly 3 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 42–1019(978 aa) 片段:UNP RESIDUES 42-1019
链 B 42–1019(978 aa) 片段:UNP RESIDUES 42-1019
突变:C110L,E111Q,C171S,C178A,C257V,C414L,C573N,C590S,C789S,C812A,C819A,C904S,C966N,C974A 突变:C110L,E111Q,C171S,C178A,C257V,C414L,C573N,C590S,C789S,C812A,C819A,C904S,C966N,C974A MGK methyl N-(carboxymethyl)-N-(3-phenylpropyl)glycyl-L-histidinate × 2 ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;287 K;10-13% PEG MME 5000, 100 MM HEPES PH 7.0, 4-14% TACSIMATE, 10% DIOXANE, VAPOR DIFFUSION, HANGING DROP, temperature 287K
分辨率 3.00 Å R-free 0.227
4GS8 Structure analysis of cysteine free insulin degrading enzyme (ide) with compound bdm43079 [{[(s)-2-(1h-imidazol-4-yl)-1-methylcarbamoyl-ethylcarbamoyl]-methyl}-(3-phenyl-propyl)-amino]-acetic acid 提交 2012-08-27 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 42–1019(978 aa) 片段:UNP RESIDUES 42-1019
突变:C110L,E111Q,C171S,C178A,C257V,C414L,C573N,C590S,C789SC812A,C819A,C904S,C966N,C974A MGJ N-(carboxymethyl)-N-(3-phenylpropyl)glycyl-N-methyl-L-histidinamide × 1 ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;10-13% PEG MME 5000, 100 MM HEPES PH 7.0, 4-14% TACSIMATE, 10% DIOXANE, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 289K
分辨率 2.99 Å R-free 0.235
4GS8 Structure analysis of cysteine free insulin degrading enzyme (ide) with compound bdm43079 [{[(s)-2-(1h-imidazol-4-yl)-1-methylcarbamoyl-ethylcarbamoyl]-methyl}-(3-phenyl-propyl)-amino]-acetic acid 提交 2012-08-27 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 42–1019(978 aa) 片段:UNP RESIDUES 42-1019
突变:C110L,E111Q,C171S,C178A,C257V,C414L,C573N,C590S,C789SC812A,C819A,C904S,C966N,C974A MGJ N-(carboxymethyl)-N-(3-phenylpropyl)glycyl-N-methyl-L-histidinamide × 1 ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;10-13% PEG MME 5000, 100 MM HEPES PH 7.0, 4-14% TACSIMATE, 10% DIOXANE, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 289K
分辨率 2.99 Å R-free 0.235
4GSC Structure analysis of insulin degrading enzyme with compound bdm41559 ((s)-2-[2-(carboxymethyl-phenethyl-amino)-acetylamino]-3-(1h-imidazol-4-yl)-propionic acid methyl ester) 提交 2012-08-27 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 42–1019(978 aa) 片段:UNP RESIDUES 42-1019
突变:C110L,E111Q,C171S,C178A,C257V,C414L,C573N,C590S,C789S,C812A,C819A,C904S,C966N,C974A ZN ZINC ION × 1 MGW methyl N-(carboxymethyl)-N-(2-phenylethyl)glycyl-L-histidinate × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;10-13% PEG MME 5000, 100 MM HEPES PH 7.0, 4-14% TACSIMATE, 10% DIOXANE, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 287K
分辨率 2.81 Å R-free 0.253
4GSC Structure analysis of insulin degrading enzyme with compound bdm41559 ((s)-2-[2-(carboxymethyl-phenethyl-amino)-acetylamino]-3-(1h-imidazol-4-yl)-propionic acid methyl ester) 提交 2012-08-27 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 42–1019(978 aa) 片段:UNP RESIDUES 42-1019
突变:C110L,E111Q,C171S,C178A,C257V,C414L,C573N,C590S,C789S,C812A,C819A,C904S,C966N,C974A ZN ZINC ION × 1 MGW methyl N-(carboxymethyl)-N-(2-phenylethyl)glycyl-L-histidinate × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;10-13% PEG MME 5000, 100 MM HEPES PH 7.0, 4-14% TACSIMATE, 10% DIOXANE, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 287K
分辨率 2.81 Å R-free 0.253
4GSC Structure analysis of insulin degrading enzyme with compound bdm41559 ((s)-2-[2-(carboxymethyl-phenethyl-amino)-acetylamino]-3-(1h-imidazol-4-yl)-propionic acid methyl ester) 提交 2012-08-27 Assembly 3 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 42–1019(978 aa) 片段:UNP RESIDUES 42-1019
链 B 42–1019(978 aa) 片段:UNP RESIDUES 42-1019
突变:C110L,E111Q,C171S,C178A,C257V,C414L,C573N,C590S,C789S,C812A,C819A,C904S,C966N,C974A 突变:C110L,E111Q,C171S,C178A,C257V,C414L,C573N,C590S,C789S,C812A,C819A,C904S,C966N,C974A ZN ZINC ION × 2 MGW methyl N-(carboxymethyl)-N-(2-phenylethyl)glycyl-L-histidinate × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;10-13% PEG MME 5000, 100 MM HEPES PH 7.0, 4-14% TACSIMATE, 10% DIOXANE, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 287K
分辨率 2.81 Å R-free 0.253
4GSF The structure analysis of cysteine free insulin degrading enzyme (ide) with (s)-2-{2-[carboxymethyl-(3-phenyl-propionyl)-amino]-acetylamino}-3-(3h-imidazol-4-yl)-propionic acid methyl ester 提交 2012-08-27 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 42–1019(978 aa) 片段:UNP RESIDUES 42-1019
突变:C110L,E111Q,C171S,C178A,C257V,C414L,C573N,C590S,C789S,C812A,C819A,C904S,C966N,C974A MGH methyl N-(carboxymethyl)-N-(3-phenylpropanoyl)glycyl-D-histidinate × 1 ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;10-13% PEG MME 5000, 100 MM HEPES PH 7.0, 4-14% TACSIMATE, 10% DIOXANE, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 287K
分辨率 2.70 Å R-free 0.220
4GSF The structure analysis of cysteine free insulin degrading enzyme (ide) with (s)-2-{2-[carboxymethyl-(3-phenyl-propionyl)-amino]-acetylamino}-3-(3h-imidazol-4-yl)-propionic acid methyl ester 提交 2012-08-27 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 42–1019(978 aa) 片段:UNP RESIDUES 42-1019
突变:C110L,E111Q,C171S,C178A,C257V,C414L,C573N,C590S,C789S,C812A,C819A,C904S,C966N,C974A MGH methyl N-(carboxymethyl)-N-(3-phenylpropanoyl)glycyl-D-histidinate × 1 ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;10-13% PEG MME 5000, 100 MM HEPES PH 7.0, 4-14% TACSIMATE, 10% DIOXANE, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 287K
分辨率 2.70 Å R-free 0.220
4IFH Crystal structure of human insulin degrading enzyme (IDE) in complex with compound BDM44619 提交 2012-12-14 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 42–1019(978 aa)
链 B 42–1019(978 aa)
突变:C110L, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A 突变:C110L, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A ZN ZINC ION × 2 1EF N-({1-[(2R)-4-(hydroxyamino)-1-(naphthalen-2-yl)-4-oxobutan-2-yl]-1H-1,2,3-triazol-4-yl}methyl)-4-methylbenzamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291.15 K;10% PEG 5000, 100mM HEPES, 14% Tacsimate, 10% Dioxane, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 291.15K
分辨率 3.29 Å R-free 0.224
4IFH Crystal structure of human insulin degrading enzyme (IDE) in complex with compound BDM44619 提交 2012-12-14 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 42–1019(978 aa)
突变:C110L, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291.15 K;10% PEG 5000, 100mM HEPES, 14% Tacsimate, 10% Dioxane, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 291.15K
分辨率 3.29 Å R-free 0.224
4IFH Crystal structure of human insulin degrading enzyme (IDE) in complex with compound BDM44619 提交 2012-12-14 Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 42–1019(978 aa)
突变:C110L, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A ZN ZINC ION × 1 1EF N-({1-[(2R)-4-(hydroxyamino)-1-(naphthalen-2-yl)-4-oxobutan-2-yl]-1H-1,2,3-triazol-4-yl}methyl)-4-methylbenzamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291.15 K;10% PEG 5000, 100mM HEPES, 14% Tacsimate, 10% Dioxane, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 291.15K
分辨率 3.29 Å R-free 0.224
4IOF Crystal structure analysis of Fab-bound human Insulin Degrading Enzyme (IDE) 提交 2013-01-07 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 A 42–1019(978 aa)
链 B 42–1019(978 aa)
未记录 ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.5;291.15 K;0.1M Sodium cacodylate, pH6.5; 0.2M MgCl2; 10% PEG3000, VAPOR DIFFUSION, HANGING DROP, temperature 291.15K
分辨率 3.35 Å R-free 0.280
4LTE Structure of Cysteine-free Human Insulin Degrading Enzyme in Complex with Macrocyclic Inhibitor 提交 2013-07-23 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 42–1019(978 aa) 片段:UNP RESIDUES 42-1019
突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A ZN ZINC ION × 1 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1 LYN 2,6-DIAMINO-HEXANOIC ACID AMIDE × 1 FUM FUMARIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;0.1 M HEPES, 20 % PEGMME-5000, 12 % tacsimate, 10 % dioxane, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
分辨率 2.71 Å R-free 0.200
4LTE Structure of Cysteine-free Human Insulin Degrading Enzyme in Complex with Macrocyclic Inhibitor 提交 2013-07-23 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 42–1019(978 aa) 片段:UNP RESIDUES 42-1019
突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A ZN ZINC ION × 1 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1 LYN 2,6-DIAMINO-HEXANOIC ACID AMIDE × 1 FUM FUMARIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;0.1 M HEPES, 20 % PEGMME-5000, 12 % tacsimate, 10 % dioxane, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
分辨率 2.71 Å R-free 0.200
4M1C Crystal Structure Analysis of Fab-Bound Human Insulin Degrading Enzyme (IDE) in Complex with Amyloid-Beta (1-40) 提交 2013-08-02 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 42–1019(978 aa)
突变:E111Q ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.5;291.15 K;0.1M Sodium cacodylate, pH6.5, 0.2M MgCl2, 10% PEG-3000, VAPOR DIFFUSION, HANGING DROP, temperature 291.15K
分辨率 3.50 Å R-free 0.270
4M1C Crystal Structure Analysis of Fab-Bound Human Insulin Degrading Enzyme (IDE) in Complex with Amyloid-Beta (1-40) 提交 2013-08-02 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 B 42–1019(978 aa)
突变:E111Q ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.5;291.15 K;0.1M Sodium cacodylate, pH6.5, 0.2M MgCl2, 10% PEG-3000, VAPOR DIFFUSION, HANGING DROP, temperature 291.15K
分辨率 3.50 Å R-free 0.270
4NXO Crystal Structure of Insulin Degrading Enzyme in complex with BDM44768 提交 2013-12-09 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 42–1019(978 aa) 片段:UNP residues 42-1019
未记录 ZN ZINC ION × 1 2H7 4-fluoro-N-({1-[(2R)-4-(hydroxyamino)-1-(naphthalen-2-yl)-4-oxobutan-2-yl]-1H-1,2,3-triazol-4-yl}methyl)benzamide × 1 1PE PENTAETHYLENE GLYCOL × 1 PEG DI(HYDROXYETHYL)ETHER × 3 EDO 1,2-ETHANEDIOL × 2 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 7;291.15 K;0.1M HEPES, pH 7.0, 10% Tacsimate, 10%Dioxane, 10% PEG-5000, VAPOR DIFFUSION, HANGING DROP, temperature 291.15K
分辨率 2.73 Å R-free 0.219
4NXO Crystal Structure of Insulin Degrading Enzyme in complex with BDM44768 提交 2013-12-09 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 42–1019(978 aa) 片段:UNP residues 42-1019
未记录 ZN ZINC ION × 1 2H7 4-fluoro-N-({1-[(2R)-4-(hydroxyamino)-1-(naphthalen-2-yl)-4-oxobutan-2-yl]-1H-1,2,3-triazol-4-yl}methyl)benzamide × 1 1PE PENTAETHYLENE GLYCOL × 1 PEG DI(HYDROXYETHYL)ETHER × 4 EDO 1,2-ETHANEDIOL × 2 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1 DIO 1,4-DIETHYLENE DIOXIDE × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 7;291.15 K;0.1M HEPES, pH 7.0, 10% Tacsimate, 10%Dioxane, 10% PEG-5000, VAPOR DIFFUSION, HANGING DROP, temperature 291.15K
分辨率 2.73 Å R-free 0.219
4PES Crystal structure of insulin degrading enzyme complexed with inhibitor tert-butyl [(2S)-2-(2,5-difluorophenyl)-3-(quinolin-3-yl)propyl]carbamate 提交 2014-04-24 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 42–1019(978 aa) 片段:UNP residues 42-1019
突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A 2PJ tert-butyl [(2S)-2-(2,5-difluorophenyl)-3-(quinolin-3-yl)propyl]carbamate × 1 ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION;298 K;20% PEG3350, 0.2 mM sodium thiocyanate
分辨率 2.21 Å R-free 0.256
4PES Crystal structure of insulin degrading enzyme complexed with inhibitor tert-butyl [(2S)-2-(2,5-difluorophenyl)-3-(quinolin-3-yl)propyl]carbamate 提交 2014-04-24 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 42–1019(978 aa) 片段:UNP residues 42-1019
突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A 2PJ tert-butyl [(2S)-2-(2,5-difluorophenyl)-3-(quinolin-3-yl)propyl]carbamate × 1 ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION;298 K;20% PEG3350, 0.2 mM sodium thiocyanate
分辨率 2.21 Å R-free 0.256
4PF7 Crystal structure of insulin degrading enzyme complexed with inhibitor 提交 2014-04-28 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 42–1019(978 aa) 片段:UNP residues 42-1019
链 B 42–1019(978 aa) 片段:UNP residues 42-1019
突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A 突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A 2QW (2S)-2-amino-N-{(1S)-1-cyclohexyl-2-[(4-methylphenyl)amino]-2-oxoethyl}-4-(methylselanyl)butanamide × 2 ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION;298 K;20% PEG3350, 0.2 mM sodium thiocyanate
分辨率 2.33 Å R-free 0.236
4PF9 Crystal structure of insulin degrading enzyme complexed with inhibitor 提交 2014-04-28 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 42–1019(978 aa) 片段:UNP residues 42-1019
链 B 42–1019(978 aa) 片段:UNP residues 42-1019
突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A 突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A 2Q6 methyl [(2S)-2-[4-({5-[4-({(2S)-2-[(3S)-3-amino-2-oxopiperidin-1-yl]-2-cyclohexylacetyl}amino)phenyl]pentyl}oxy)phenyl]-3-(quinolin-3-yl)propyl]carbamate × 2 ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION;298 K;20% PEG3350, 0.2 mM sodium thiocyanate
分辨率 2.50 Å R-free 0.253
4PFC Crystal structure of insulin degrading enzyme complexed with inhibitor 提交 2014-04-28 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 42–1019(978 aa) 片段:UNP residues 42-1019
链 B 42–1019(978 aa) 片段:UNP residues 42-1019
突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A 突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A 2QX methyl [(2S)-2-(5-{5-[4-({(2S)-2-[(3S)-3-amino-2-oxopiperidin-1-yl]-2-cyclohexylacetyl}amino)phenyl]pentyl}-2-fluorophenyl)-3-(quinolin-3-yl)propyl]carbamate × 2 ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION;298 K;20% PEG3350, 0.2 mM sodium thiocyanate
分辨率 2.21 Å R-free 0.233
4QIA Crystal structure of human insulin degrading enzyme (ide) in complex with inhibitor N-benzyl-N-(carboxymethyl)glycyl-L-histidine 提交 2014-05-30 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 42–1019(978 aa)
未记录 33K N-benzyl-N-(carboxymethyl)glycyl-L-histidine × 1 ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;287 K;10-13% PEG MME 5000, 100 MM HEPES PH 7.0, 4-14% TACSIMATE, 10% DIOXANE, VAPOR DIFFUSION, HANGING DROP, temperature 287K
分辨率 3.20 Å R-free 0.222
4QIA Crystal structure of human insulin degrading enzyme (ide) in complex with inhibitor N-benzyl-N-(carboxymethyl)glycyl-L-histidine 提交 2014-05-30 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 42–1019(978 aa)
未记录 33K N-benzyl-N-(carboxymethyl)glycyl-L-histidine × 1 ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;287 K;10-13% PEG MME 5000, 100 MM HEPES PH 7.0, 4-14% TACSIMATE, 10% DIOXANE, VAPOR DIFFUSION, HANGING DROP, temperature 287K
分辨率 3.20 Å R-free 0.222
4RAL Crystal structure of insulin degrading enzyme in complex with macrophage inflammatory protein 1 beta 提交 2014-09-10 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 42–1019(978 aa) 片段:UNP residues 42-1019
突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291 K;13% PEG5000 MME, 100 mM HEPES, pH 7.0, 10% Tacsimate, 10% dioxane, VAPOR DIFFUSION, HANGING DROP, temperature 291.0K
分辨率 3.15 Å R-free 0.255
4RAL Crystal structure of insulin degrading enzyme in complex with macrophage inflammatory protein 1 beta 提交 2014-09-10 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 42–1019(978 aa) 片段:UNP residues 42-1019
突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291 K;13% PEG5000 MME, 100 mM HEPES, pH 7.0, 10% Tacsimate, 10% dioxane, VAPOR DIFFUSION, HANGING DROP, temperature 291.0K
分辨率 3.15 Å R-free 0.255
4RE9 Crystal structure of human insulin degrading enzyme (IDE) in complex with compound 71290 提交 2014-09-22 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 42–1019(978 aa) 片段:UNP residues 42-1019
突变:C110L, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A ZN ZINC ION × 1 3M9 4-fluoro-N-({1-[(2R)-4-(hydroxyamino)-1-(naphthalen-2-yl)-4-oxobutan-2-yl]-1H-1,2,3-triazol-5-yl}methyl)benzamide × 1 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1 PEG DI(HYDROXYETHYL)ETHER × 6 1PE PENTAETHYLENE GLYCOL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291.15 K;10% PEG5000, 100 mM HEPES, 14% Tacsimate, 10% dioxane, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 291.15K
分辨率 2.91 Å R-free 0.213
4RE9 Crystal structure of human insulin degrading enzyme (IDE) in complex with compound 71290 提交 2014-09-22 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 42–1019(978 aa) 片段:UNP residues 42-1019
突变:C110L, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A ZN ZINC ION × 1 3M9 4-fluoro-N-({1-[(2R)-4-(hydroxyamino)-1-(naphthalen-2-yl)-4-oxobutan-2-yl]-1H-1,2,3-triazol-5-yl}methyl)benzamide × 1 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1 PEG DI(HYDROXYETHYL)ETHER × 4 1PE PENTAETHYLENE GLYCOL × 1 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291.15 K;10% PEG5000, 100 mM HEPES, 14% Tacsimate, 10% dioxane, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 291.15K
分辨率 2.91 Å R-free 0.213
5CJO Crystal Structure Analysis of Elbow-Engineered-Fab-Bound Human Insulin Degrading Enzyme (IDE) in Complex with Insulin 提交 2015-07-14 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 8 PDB 声明:octameric(8) 与蛋白数一致
链 A 42–1019(978 aa)
突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 2 ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291.15 K;6% v/v Tacsimate pH 7.0, 0.1 M HEPES pH 7.0, 8% w/v Polyethylene glycol monomethyl ether 5,000, and 8% v/v tert-butanol as additive.
分辨率 3.29 Å R-free 0.245
5UOE Crystal Structure Analysis of Elbow-Engineered-Fab-Bound Human Insulin Degrading Enzyme (IDE) 提交 2017-01-31 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 A 42–1019(978 aa)
突变:C110L, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A. 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291.15 K;0.088M Ammonium citrate tribasic, ph 7, 10% w/v peg3350, 0.02 M Ethylenediaminetetraacetic disodium salt dihydrate
分辨率 3.80 Å R-free 0.270
5UOE Crystal Structure Analysis of Elbow-Engineered-Fab-Bound Human Insulin Degrading Enzyme (IDE) 提交 2017-01-31 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 B 42–1019(978 aa)
突变:C110L, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A. 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291.15 K;0.088M Ammonium citrate tribasic, ph 7, 10% w/v peg3350, 0.02 M Ethylenediaminetetraacetic disodium salt dihydrate
分辨率 3.80 Å R-free 0.270
5UOE Crystal Structure Analysis of Elbow-Engineered-Fab-Bound Human Insulin Degrading Enzyme (IDE) 提交 2017-01-31 Assembly 3 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 C 42–1019(978 aa)
突变:C110L, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A. 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291.15 K;0.088M Ammonium citrate tribasic, ph 7, 10% w/v peg3350, 0.02 M Ethylenediaminetetraacetic disodium salt dihydrate
分辨率 3.80 Å R-free 0.270
5UOE Crystal Structure Analysis of Elbow-Engineered-Fab-Bound Human Insulin Degrading Enzyme (IDE) 提交 2017-01-31 Assembly 4 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 D 42–1019(978 aa)
突变:C110L, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A. 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291.15 K;0.088M Ammonium citrate tribasic, ph 7, 10% w/v peg3350, 0.02 M Ethylenediaminetetraacetic disodium salt dihydrate
分辨率 3.80 Å R-free 0.270
5UOE Crystal Structure Analysis of Elbow-Engineered-Fab-Bound Human Insulin Degrading Enzyme (IDE) 提交 2017-01-31 Assembly 5 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 E 42–1019(978 aa)
突变:C110L, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A. 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291.15 K;0.088M Ammonium citrate tribasic, ph 7, 10% w/v peg3350, 0.02 M Ethylenediaminetetraacetic disodium salt dihydrate
分辨率 3.80 Å R-free 0.270
5WOB Crystal Structure Analysis of Fab1-Bound Human Insulin Degrading Enzyme (IDE) in Complex with Insulin 提交 2017-08-01 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 8 PDB 声明:octameric(8) 与蛋白数一致
链 A 42–1019(978 aa) 片段:UNP residues 42-1019
链 B 42–1019(978 aa) 片段:UNP residues 42-1019
未记录 ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.5;291.15 K;0.1M Sodium cacodylate, pH6.5; 0.2M MgCl2; 10% PEG3000, VAPOR DIFFUSION, HANGING DROP, temperature 291.15K
分辨率 3.95 Å R-free 0.291
5WOB Crystal Structure Analysis of Fab1-Bound Human Insulin Degrading Enzyme (IDE) in Complex with Insulin 提交 2017-08-01 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 8 PDB 声明:octameric(8) 与蛋白数一致
链 C 42–1019(978 aa) 片段:UNP residues 42-1019
链 D 42–1019(978 aa) 片段:UNP residues 42-1019
未记录 ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.5;291.15 K;0.1M Sodium cacodylate, pH6.5; 0.2M MgCl2; 10% PEG3000, VAPOR DIFFUSION, HANGING DROP, temperature 291.15K
分辨率 3.95 Å R-free 0.291
5WOB Crystal Structure Analysis of Fab1-Bound Human Insulin Degrading Enzyme (IDE) in Complex with Insulin 提交 2017-08-01 Assembly 3 蛋白异源复合物 异源复合物;蛋白 × 8 PDB 声明:octameric(8) 与蛋白数一致
链 E 42–1019(978 aa) 片段:UNP residues 42-1019
链 F 42–1019(978 aa) 片段:UNP residues 42-1019
未记录 ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.5;291.15 K;0.1M Sodium cacodylate, pH6.5; 0.2M MgCl2; 10% PEG3000, VAPOR DIFFUSION, HANGING DROP, temperature 291.15K
分辨率 3.95 Å R-free 0.291
5WOB Crystal Structure Analysis of Fab1-Bound Human Insulin Degrading Enzyme (IDE) in Complex with Insulin 提交 2017-08-01 Assembly 4 蛋白异源复合物 异源复合物;蛋白 × 8 PDB 声明:octameric(8) 与蛋白数一致
链 G 42–1019(978 aa) 片段:UNP residues 42-1019
链 H 42–1019(978 aa) 片段:UNP residues 42-1019
未记录 ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.5;291.15 K;0.1M Sodium cacodylate, pH6.5; 0.2M MgCl2; 10% PEG3000, VAPOR DIFFUSION, HANGING DROP, temperature 291.15K
分辨率 3.95 Å R-free 0.291
6B3Q Cryo-EM structure of human insulin degrading enzyme in complex with insulin 提交 2017-09-22 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 42–1019(978 aa) 片段:residues 42-1019
链 B 42–1019(978 aa) 片段:residues 42-1019
未记录 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.8
cryo-EM玻璃化条件 冷冻剂 ETHANE;The cryo grids were made using Spotiton and homemade plunger
分辨率 3.70 Å
6B70 Cryo-EM structure of human insulin degrading enzyme in complex with FAB H11-E heavy chain, FAB H11-E light chain and insulin 提交 2017-10-03 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 8 PDB 声明:octameric(8) 与蛋白数一致
链 A 46–1011(966 aa) 片段:residues 46-1011
链 B 46–1011(966 aa) 片段:residues 46-1011
未记录 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.8
cryo-EM玻璃化条件 冷冻剂 ETHANE;The cryo grids were made using Spotiton and homemade plunger
分辨率 3.70 Å
6B7Y Cryo-EM structure of human insulin degrading enzyme 提交 2017-10-05 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 46–1011(966 aa) 片段:residues 46-1011
链 B 46–1011(966 aa) 片段:residues 46-1011
未记录 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.8
cryo-EM玻璃化条件 冷冻剂 ETHANE;The cryo grids were made using Spotiton
分辨率 6.50 Å
6B7Z Cryo-EM structure of human insulin degrading enzyme in complex with FAB H11 heavy chain and FAB H11 light chain 提交 2017-10-05 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 A 46–1011(966 aa) 片段:residues 46-1011
链 B 46–1011(966 aa) 片段:residues 46-1011
未记录 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.8
cryo-EM玻璃化条件 冷冻剂 ETHANE;The cryo grids were made using Spotiton
分辨率 6.50 Å
6BF6 Cryo-EM structure of human insulin degrading enzyme 提交 2017-10-26 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 46–1011(966 aa) 片段:residues 46-1011
链 B 46–1011(966 aa) 片段:residues 46-1011
未记录 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.8
cryo-EM玻璃化条件 冷冻剂 ETHANE;The cryo grids were made using Spotiton
分辨率 6.50 Å
6BF7 Cryo-EM structure of human insulin degrading enzyme in complex with FAB H11-E heavy chain, FAB H11-E light chain 提交 2017-10-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 A 46–1011(966 aa) 片段:residues 46-1011
链 B 46–1011(966 aa) 片段:residues 46-1011
未记录 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.8
cryo-EM玻璃化条件 冷冻剂 ETHANE;The cryo grids were made using Spotiton
分辨率 6.50 Å
6BF8 Cryo-EM structure of human insulin degrading enzyme in complex with insulin 提交 2017-10-26 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 46–1011(966 aa) 片段:residues 46-1011
链 B 46–1011(966 aa) 片段:residues 46-1011
未记录 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.8
cryo-EM玻璃化条件 冷冻剂 ETHANE;The cryo grids were made using Spotiton
分辨率 4.20 Å
6BF9 Cryo-EM structure of human insulin degrading enzyme in complex with FAB H11-E heavy chain, FAB H11-E light chain 提交 2017-10-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 A 46–1011(966 aa) 片段:residues 46-1011
链 B 46–1011(966 aa) 片段:residues 46-1011
未记录 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.8
cryo-EM玻璃化条件 冷冻剂 ETHANE;The cryo grids were made using Spotiton
分辨率 7.20 Å
6BFC Cryo-EM structure of human insulin degrading enzyme in complex with insulin 提交 2017-10-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 46–1011(966 aa)
链 B 46–1011(966 aa)
未记录 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.8
cryo-EM玻璃化条件 冷冻剂 ETHANE;Grids made using Spotiton
分辨率 3.70 Å
6BYZ Structure of Cysteine-free Human Insulin-Degrading Enzyme in complex with Substrate-selective Macrocyclic Inhibitor 37 提交 2017-12-21 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 1–1019(1019 aa)
突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A J18 [(8R,9S,10S)-9-(2',3'-dimethyl[1,1'-biphenyl]-4-yl)-6-{[2-(trifluoromethyl)phenyl]sulfonyl}-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol × 1 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.8;298 K;0.1 M HEPES, 12% Tacsimate, 20% PEGMME-5000, 10% 1,4-dioxane
分辨率 2.96 Å R-free 0.203
6BYZ Structure of Cysteine-free Human Insulin-Degrading Enzyme in complex with Substrate-selective Macrocyclic Inhibitor 37 提交 2017-12-21 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 1–1019(1019 aa)
突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A J18 [(8R,9S,10S)-9-(2',3'-dimethyl[1,1'-biphenyl]-4-yl)-6-{[2-(trifluoromethyl)phenyl]sulfonyl}-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol × 1 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.8;298 K;0.1 M HEPES, 12% Tacsimate, 20% PEGMME-5000, 10% 1,4-dioxane
分辨率 2.96 Å R-free 0.203
6EDS Structure of Cysteine-free Human Insulin-Degrading Enzyme in complex with Glucagon and Substrate-selective Macrocyclic Inhibitor 63 提交 2018-08-10 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 42–1019(978 aa)
突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A J22 {(8R,9S,10S)-9-(2',3'-dimethyl[1,1'-biphenyl]-4-yl)-6-[(1-methyl-1H-imidazol-2-yl)sulfonyl]-1,6-diazabicyclo[6.2.0]decan-10-yl}methanol × 1 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1 PEG DI(HYDROXYETHYL)ETHER × 1 DIO 1,4-DIETHYLENE DIOXIDE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;298 K;0.1M HEPES pH 7.0, 12% Tacsimate pH 7.0, 13% PEGMME, 10% Dioxane
分辨率 3.18 Å R-free 0.222
6EDS Structure of Cysteine-free Human Insulin-Degrading Enzyme in complex with Glucagon and Substrate-selective Macrocyclic Inhibitor 63 提交 2018-08-10 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 42–1019(978 aa)
突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A J22 {(8R,9S,10S)-9-(2',3'-dimethyl[1,1'-biphenyl]-4-yl)-6-[(1-methyl-1H-imidazol-2-yl)sulfonyl]-1,6-diazabicyclo[6.2.0]decan-10-yl}methanol × 1 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1 PEG DI(HYDROXYETHYL)ETHER × 1 DIO 1,4-DIETHYLENE DIOXIDE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;298 K;0.1M HEPES pH 7.0, 12% Tacsimate pH 7.0, 13% PEGMME, 10% Dioxane
分辨率 3.18 Å R-free 0.222
6MQ3 Structure of Cysteine-free Human Insulin-Degrading Enzyme in complex with Substrate-selective Macrocycle Inhibitor 63 提交 2018-10-09 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:monomeric(1) 待复核
链 A 42–1019(978 aa)
链 B 42–1019(978 aa)
突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A 突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A J22 {(8R,9S,10S)-9-(2',3'-dimethyl[1,1'-biphenyl]-4-yl)-6-[(1-methyl-1H-imidazol-2-yl)sulfonyl]-1,6-diazabicyclo[6.2.0]decan-10-yl}methanol × 2 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;298 K;0.1M HEPES pH 6.5, 5% Tacsimate pH 7, 10% 1,4-Dioxane, 14% PEGGMME 5000
分辨率 3.57 Å R-free 0.211
6MQ3 Structure of Cysteine-free Human Insulin-Degrading Enzyme in complex with Substrate-selective Macrocycle Inhibitor 63 提交 2018-10-09 Assembly 2 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:monomeric(1) 待复核
链 A 42–1019(978 aa)
链 B 42–1019(978 aa)
突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A 突变:C110L, E111Q, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966N, C974A J22 {(8R,9S,10S)-9-(2',3'-dimethyl[1,1'-biphenyl]-4-yl)-6-[(1-methyl-1H-imidazol-2-yl)sulfonyl]-1,6-diazabicyclo[6.2.0]decan-10-yl}methanol × 2 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;298 K;0.1M HEPES pH 6.5, 5% Tacsimate pH 7, 10% 1,4-Dioxane, 14% PEGGMME 5000
分辨率 3.57 Å R-free 0.211
7K1D Crystal structure of human insulin degrading enzyme (IDE) in complex with compound BDM_77291 提交 2020-09-07 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 42–1019(978 aa)
链 B 42–1019(978 aa)
未记录 ZN ZINC ION × 2 VQD (3R)-3-{4-[(3R)-4-(3,4-difluorobenzene-1-carbonyl)morpholin-3-yl]-1H-1,2,3-triazol-1-yl}-N-hydroxy-4-(naphthalen-2-yl)butanamide × 2 DIO 1,4-DIETHYLENE DIOXIDE × 6 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291.15 K;10% PEG 5000, 100mM HEPES, 14% Tacsimate, 10% Dioxane, pH 7.0
分辨率 3.00 Å R-free 0.192
7K1E Crystal structure of human insulin degrading enzyme (IDE) in complex with compound BDM_88646 提交 2020-09-07 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 42–1019(978 aa)
链 B 42–1019(978 aa)
未记录 ZN ZINC ION × 2 VQG 3,4-difluoro-N-[(1S)-1-{1-[(2R)-4-(hydroxyamino)-4-oxo-1-(5,6,7,8-tetrahydronaphthalen-2-yl)butan-2-yl]-1H-1,2,3-triazol-4-yl}ethyl]benzamide × 2 DIO 1,4-DIETHYLENE DIOXIDE × 6 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;291.15 K;10% PEG 5000, 100mM HEPES, 14% Tacsimate, 10% Dioxane, pH 7.0
分辨率 2.80 Å R-free 0.209
7K1F Crystal structure of human insulin degrading enzyme (IDE) in complex with compound BDM_88558 提交 2020-09-07 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 42–1019(978 aa)
链 B 42–1019(978 aa)
未记录 ZN ZINC ION × 2 VQJ 3,4-difluoro-N-({1-[(2R)-4-(hydroxyamino)-4-oxo-1-(quinolin-7-yl)butan-2-yl]-1H-1,2,3-triazol-4-yl}methyl)benzamide × 2 DIO 1,4-DIETHYLENE DIOXIDE × 6 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291.15 K;10% PEG 5000, 100mM HEPES, 14% Tacsimate, 10% Dioxane, pH 7.0
分辨率 2.60 Å R-free 0.208
7RZE Insulin Degrading Enzyme pO/pC 提交 2021-08-27 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 1–1011(1011 aa)
链 B 1–1011(1011 aa)
突变:C110L, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966S, C974S 突变:C110L, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966S, C974S 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.2
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.30 Å
7RZF Insulin Degrading Enzyme O/pC 提交 2021-08-27 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 1–1011(1011 aa)
链 B 1–1011(1011 aa)
突变:C110L, C171S, C178A, 257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966S, C974S 突变:C110L, C171S, C178A, 257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966S, C974S 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.2
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.40 Å
7RZG Insulin Degrading Enzyme O/pO 提交 2021-08-27 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 1–1011(1011 aa)
链 B 1–1011(1011 aa)
突变:C110L, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966S, C974S 突变:C110L, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966S, C974S 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.2
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 4.10 Å
7RZH Insulin Degrading Enzyme O/O 提交 2021-08-27 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 1–1011(1011 aa)
链 B 1–1011(1011 aa)
未记录 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.2
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.80 Å
7RZI Insulin Degrading Enzyme pC/pC 提交 2021-08-27 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 A 1–1011(1011 aa)
链 B 1–1011(1011 aa)
突变:C110L, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966S, C974S 突变:C110L, C171S, C178A, C257V, C414L, C573N, C590S, C789S, C812A, C819A, C904S, C966S, C974S 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.2
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.00 Å
9Y0H Insulin Degrading Enzyme Time-resolved O/O state 提交 2025-08-28 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 1–1011(1011 aa)
链 B 1–1011(1011 aa)
未记录 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 5.10 Å